KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Jan 3, 2014
Insider Transaction Report
Form 4
Webster Jeffrey D
Senior VP, Operations
Transactions
- Exercise/Conversion
Common Stock
2014-01-02$0.76/sh+3,100$2,356→ 3,100 total - Sale
Common Stock
2014-01-02$37.27/sh−3,100$115,531→ 0 total - Exercise/Conversion
Common Stock
2014-01-02$0.76/sh+900$684→ 900 total - Sale
Common Stock
2014-01-02$37.78/sh−900$34,004→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2014-01-02−3,100→ 55,661 totalExercise: $0.76Exp: 2017-03-13→ Common Stock (3,100 underlying) - Exercise/Conversion
Stock Option (right to buy)
2014-01-02−900→ 54,761 totalExercise: $0.76Exp: 2017-03-13→ Common Stock (900 underlying)
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
- [F2]100% of the shares subject to the option are fully vested and exercisable.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $36.71 to $37.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $37.71 to $37.87, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.